POINT/COUNTERPOINT: Is There a Role for HCT as Upfront Therapy for Myelofibrosis in the Era of JAK Inhibitors? "Yes"

Track: BMT Tandem "Scientific" Meeting
Saturday, March 1, 2014, 10:30 AM-12:00 PM
Texas C (Gaylord Texan)
H Joachim Deeg, MD , Clinical Research Division, Transplantation Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA
Audio File Recorded Presentation
Disclosures:
Nothing To Disclose
See more of: Myeloproliferative Neoplasms: Biological and Therapeutic Advances
See more of: BMT Tandem "Scientific" Meeting
<< Previous Presentation | Next Presentation